Differential Expression of a Mycobacterium tuberculosis Protein Recognized by a Mouse Monoclonal Antibody

Murine monoclonal antibodies were produced against Mycobacterium tuberculosis (Mtb) using standard hybridoma procedures. By a whole cell enzyme-linked immunosorbent assay (ELISA), one monoclonal antibody (mAb), HB28, demonstrated high level specific reactivity to Mtb. Western blot analysis demonstrated reactivity to a single 65 kDa Mtb protein in the cell wall extract and culture filtrate. HB28 mAb appears to be recognizing a 65 kDa Mtb protein that is over-expressed by Mtb but not other species under certain culture conditions. Differential expression and detection of this protein by HB28 mAb may have potential for diagnostic applications.     

PCR法快速检测临床标本中结核杆菌DNA

应用聚合酶链反应（ＰＣＲ）快速检测临床标本（脑脊液、胸水、腹水、血、痰液）中的结核杆菌ＤＮＡ,特异性扩增片段１２３ｂｐ,为结核杆菌的特异性重复序列ＩＳ６１１０部分基因。ＰＣＲ检测人型结核杆菌的敏感性达１０ｆｇＤＮＡ。临床标本的ＰＣＲ检测阳性率（２３．３％）明显高于抗酸染色涂片（２．９％）和细菌培养（５．７％）的阳性率（Ｐ〈０．０５）。通过设立对照系统及对扩增产物酶切分析,表明该法无假阴性结果（特异     

Pleural Fluid Adenosine Deaminase and Lymphocyte Proportion: Clinical Usefulness In the Diagnosis of Tuberculosis

Adenosine deaminase (ADA) and lymphocyte proportion are known to be independently elevated in tuberculous effusions, but are non-specific, and false positive results are frequent. to overcome this problem the combined use of both parameters was prospectively studied in 276 patients with pleural effusion seen at Porto Alegre, Brazil. Using a cut-off level of 40 U/l at 37°C (method of Giusti¹⁹) for ADA activity and lymphocyte proportion of more than 50%, the correct diagnosis of tuberculosis (sensitivity) was made in 90.7% (CI 87.3–94.1%) of 54 patients. A specificity of 97.7% (CI 95.9–99.5%) was recorded. Five false positive diagnoses of tuberculous effusion were made. Five false negative diagnoses were made: three cases with haematogenous tuberculous dissemination with low ADA levels, and two other patients with low lymphocyte proportion. the combined use of ADA activity determination and lymphocyte proportion is a highly efficient diagnostic strategy of low cost, that merits wider use.     

肺癌患者与肺结核患者血清蛋白的电泳分析

采用SDS聚丙烯酰胺凝胶电泳银染色的方法,对58例肺癌患者和32例肺结核患者的血清蛋白进行比较分析,发现有五种特异蛋白,分别存在于A区、C区、F区和G区。肺癌组和肺结核组比较,存在极显著性差异(P<0.01),提示有早期诊断肺癌的价值,有可能成为临床诊断肺癌的一个重要参考指标。     

Molecular and cellular remodeling of HepG2 cells upon treatment with antitubercular drugs

Drug-induced liver injury (DILI) is an adverse outcome of the currently used tuberculosis treatment regimen, which results in patient noncompliance, poor treatment outcomes, and the emergence of drug-resistant tuberculosis. DILI is primarily caused by the toxicity of the drugs and their metabolites, which affect liver cells, biliary epithelial cells, and liver vasculature. However, the precise mechanism behind the cellular damage attributable to first-line antitubercular drugs (ATDs), as well as the effect of toxicity on the cell survival strategies, is yet to be elucidated. In the current study, HepG2 cells upon treatment with a high concentration of ATDs showed increased perforation within the cell, cuboidal shape, and membrane blebbing as compared with control/untreated cells. It was observed that ATD-induced toxicity in HepG2 cells leads to altered mitochondrial membrane permeability, which was depicted by the decreased fluorescence intensity of the MitoRed tracker dye at higher drug concentrations. In addition, high doses of ATDs caused cell damage through an increase in reactive oxygen species production in HepG2 cells and a simultaneous reduction in glutathione levels. Further, high dose of isoniazid (50–200 mM), pyrazinamide (50–200 mM), and rifampicin (20–100 µM) causes cell apoptosis and affects cell survival during toxic conditions by decreasing the expression of potent autophagy markers Atg5, Atg7, and LC3B. Thus, ATD-mediated toxicity contributes to the reduced ability of hepatocytes to tolerate cellular damage caused by altered mitochondrial membrane permeability, increased apoptosis, and decreased autophagy. These findings further emphasize the need to develop adjuvant therapies that can mitigate ATD-induced toxicity for the effective treatment of tuberculosis.     

Mycobacterium kansasii infection in squirrel monkeys (Saimiri sciureus sciureus)

Abstract: This report documents asymptomatic infections of Mycobacterium kansasii in four of five tuberculin positive squirrel monkeys (Saimiri sciureus sciureus). The mycobacterial DNA amplified by polymerase chain reaction (PCR) from a bronchial lymph node had no affinity for the species specific probes of M. tuberculosis, M. avium, and M. intracellular, thus allowing the presumptive diagnosis of an atypical mycobacterial infection. Infection by Mycobacterium kansasii was confirmed by culture of bronchial lymph nodes from three monkeys. The source of the infection was never identified.     

莫西沙星联合用药方案对耐多药肺结核患者血清游离氨基酸和免疫功能的影响

目的:探讨莫西沙星联合用药方案对耐多药肺结核(MDR-TB)患者血清游离氨基酸和免疫功能的影响。方法:选取2015年9月到2018年1月期间我院收治的90例MDR-TB患者,根据乱数表法将患者分为研究组(n=45)、对照组(n=45),其中对照组给予左氧氟沙星联合常规化疗治疗,研究组则给予莫西沙星联合常规化疗治疗,比较两组临床疗效、痰菌转阴率、病灶吸收率、空洞闭合率、血清游离氨基酸和免疫功能,记录两组治疗期间不良反应情况。结果:研究组治疗18个月后的临床总有效率为71.11%(32/45),高于对照组的46.67%(21/45)(P0.05)。研究组治疗18个月后痰菌转阴率、病灶吸收率、空洞闭合率均较对照组高(P0.05)。两组患者治疗18个月后CD4+、免疫球蛋白A(Ig A)、免疫球蛋白G(Ig G)均升高,CD8+降低(P0.05),研究组治疗18个月后CD4+、Ig A、Ig G高于对照组,而CD8+低于对照组(P0.05)。两组治疗18个月后缬氨酸、谷氨酸均升高,且研究组高于对照组(P0.05)。两组患者总不良反应发生率比较无明显差异(P0.05)。结论:莫西沙星联合常规化疗治疗MDR-TB的疗效确切,可有效改善患者血清游离氨基酸水平,提高机体免疫功能,同时不增加不良反应发生率。     

结核分枝杆菌小RNA及其作用的研究进展

细菌小RNA是一类长度在50～500个核苷酸之间的不具有编码蛋白质功能,但具有转录后调控作用的RNA,在细菌中参与调控细菌多种生理和病理活动,如调节细菌代谢和毒力作用等过程。近年来,在结核分枝杆菌已经鉴定出近200种小RNA,并证明这些小RNA参与结核分枝杆菌的生理和病理过程。本文对结核分枝杆菌小RNA在细菌生长繁殖、毒力因子调控、细菌耐药和巨噬细胞内应激环境的适应等方面的作用进行综述。     

环丝氨酸联合莫西沙星治疗耐多药肺结核的疗效及对免疫功能和生活质量的影响

摘要 目的：探讨环丝氨酸联合莫西沙星治疗耐多药肺结核（MDR-TB）的疗效及对免疫功能和生活质量的影响。方法：选取2016年7月到2018年10月期间我院收治的MDR-TB患者86例作为研究对象,根据奇偶排序法将患者分为对照组（n=43,基础治疗联合莫西沙星治疗）和研究组（n=43,对照组基础上联合环丝氨酸治疗）,均治疗20个月。对比两组疗效、痰结核菌转阴率、病灶吸收率、空洞缩小率情况、免疫功能、生活质量及不良反应。结果：研究组治疗20个月后的总有效率高于对照组（P<0.05）。研究组治疗12个月后、治疗20个月后痰结核菌转阴率、病灶吸收率、空洞缩小率均高于对照组（P<0.05）。两组治疗20个月后心理功能、躯体功能、社会功能、物质生活评分均升高,且研究组高于对照组（P<0.05）。两组治疗20个月后CD8⁺较治疗前降低,且研究组低于对照组（P<0.05）,CD3⁺、CD4⁺/CD8⁺、CD4⁺较治疗前升高,且研究组高于对照组（P<0.05）。对比两组不良反应发生率无差异（P>0.05）。结论：环丝氨酸联合莫西沙星治疗MDR-TB,能够有效的促进患者机体免疫功能和生活质量的改善,并能够有效的促进临床转归,且用药安全性较高。